The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis

Takaya Abe, Hidenori Matsuo, Ryuzo Abe, Shinji Abe, Hiroaki Asada, Akira Ashida, Akiyasu Baba, Kei Eguchi, Yutaka Eguchi, Yoshihiro Endo, Yoshihiro Fujimori, Kengo Furuichi, Yutaka Furukawa, Mayumi Furuya, Tomoki Furuya, Norio Hanafusa, Wataru Hara, Mariko Harada-Shiba, Midori Hasegawa, Noriyuki HattoriMotoshi Hattori, Sumi Hidaka, Toshihiko Hidaka, Chika Hirayama, Shigaku Ikeda, Hideaki Imamura, Kazuaki Inoue, Keita Ishizuka, Kiyonobu Ishizuka, Takafumi Ito, Hitomi Iwamoto, Syoko Izaki, Maki Kagitani, Shuzo Kaneko, Naoto Kaneko, Takuro Kanekura, Kiyoki Kitagawa, Makio Kusaoi, Youwei Lin, Takeshi Maeda, Hisashi Makino, Shigeki Makino, Kenichi Matsuda, Takao Matsugane, Yusuke Minematsu, Michio Mineshima, Kenichiro Miura, Katsuichi Miyamoto, Takeshi Moriguchi, Mayumi Murata, Makoto Naganuma, Hajime Nakae, Shinya Narukawa, Atsushi Nohara, Kyoichi Nomura, Hirofumi Ochi, Atsushi Ohkubo, Takayasu Ohtake, Kazuya Okada, Tomokazu Okado, Yoshiki Okuyama, Susumu Omokawa, Satoru Oji, Norihiko Sakai, Yuichiro Sakamoto, Shigeru Sasaki, Motoyoshi Sato, Mariko Seishima, Hidetoshi Shiga, Homare Shimohata, Noriko Sugawara, Kohei Sugimoto, Yasushi Suzuki, Masato Suzuki, Takashi Tajima, Yasuhiro Takikawa, Satoru Tanaka, Kenjiro Taniguchi, Satoko Tsuchida, Tatsuo Tsukamoto, Kenji Tsushima, Yasunori Ueda, Takashi Wada, Hiromichi Yamada, Hiroyuki Yamada, Toshihiko Yamaka, Ken'ichiro Yamamoto, Yoko Yokoyama, Norihito Yoshida, Toyokazu Yoshioka, Ken Yamaji

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Most of the diseases for which apheresis therapy is indicated are intractable and rare, and each patient has a different background and treatment course prior to apheresis therapy initiation. Therefore, it is difficult to conduct large-scale randomized controlled trials to secure high-quality evidence. Under such circumstances, the American Society for Apheresis (ASFA) issued its guidelines in 2007, which were repeatedly revised until the latest edition in 2019. The ASFA guidelines are comprehensive. However, in the United States, a centrifugal separation method is mainly used for apheresis, whereas the mainstream procedure in Japan is the membrane separation method. The target diseases and their backgrounds are different from those in Japan. Due to these differences, the direct adoption of the ASFA guidelines in Japanese practice creates various problems. One of the features of apheresis in Japan is the development of treatment methods using hollow-fiber devices such as double filtration plasmapheresis (DFPP) and selective plasma exchange and adsorption-type devices such as polymyxin B-immobilized endotoxin adsorption columns. Specialists in emergency medicine, hematology, collagen diseases/rheumatology, respiratory medicine, cardiovascular medicine, gastroenterology, neurology, nephrology, and dermatology who are familiar with apheresis therapy gathered for this guideline, which covers 86 diseases. In addition, since apheresis therapy involves not only physicians but also clinical engineers, nurses, dieticians, and many other medical professionals, this guideline was prepared in the form of a worksheet so that it can be easily understood at the bedside. Moreover, to the clinical purposes, this guideline is designed to summarize apheresis therapy in Japan and to disseminate and further develop Japanese apheresis technology to the world. As diagnostic and therapeutic techniques are constantly advancing, the guidelines need to be revised every few years. In order to ensure the high quality of apheresis therapy in Japan, both the Japanese Society for Apheresis Registry and the guidelines will be inseparable.

Original languageEnglish
Pages (from-to)728-876
Number of pages149
JournalTherapeutic Apheresis and Dialysis
Volume25
Issue number6
DOIs
Publication statusPublished - 12-2021

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Fingerprint

Dive into the research topics of 'The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis'. Together they form a unique fingerprint.

Cite this